Use of chronic medications among a large, commercially-insured US population

被引:13
|
作者
Roe, CM
McNamara, AM
Motheral, BR
机构
[1] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
[2] Express Scripts Inc, Womens Hlth, Maryland Hts, MO 63043 USA
[3] Express Scripts Inc, Outcomes Res, Maryland Hts, MO USA
关键词
chronic medication use; gender differences; sex differences; pharmacy claim database;
D O I
10.1002/pds.700
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose To examine use of chronic therapies by females and males of all ages. Methods Participants were 1295 948 members of a large US pharmacy benefit manager. The use of chronic medications by males and females during 1999 was examined overall and within 16 commonly-used chronic drug groups. Dependent variables were use of a drug group, number of drug groups used, number of prescriptions filled and sum of costs, both within each drug group and overall, Combination therapy was defined as using at least two of the 16 chronic therapy groups during 1999. Results Females were more likely than males to use chronic medications during the study year (36.5 vs. 22.4%, p < 0.001). Generally, the likelihood of using a chronic medication increased with age for both sexes. Commonly-used chronic medications accounted for 54 and 50% of prescriptions for females and males respectively, and for 53% of total drug costs for both sexes. There were few meaningful sex differences in the likelihood of using particular drug groups. Of those who took chronic drugs 14% used combination chronic therapy. Conclusions This study provides demographic information regarding treatment of chronic conditions that can be used to aid policy decisions and to provide an impetus for future research. Copyright (C) 2002 John Wiley & Sons, Ltd.
引用
收藏
页码:301 / 309
页数:9
相关论文
共 50 条
  • [31] FACTORS INFLUENCING THE USE OF MASTECTOMY AMONG WOMEN WITH BREAST CANCER IN A COMMERCIALLY INSURED US POPULATION
    Khanna, R.
    Kalsekar, I
    Bamow, A.
    Canfield, T.
    Liao, R.
    Yadalam, S.
    Alderman, A.
    VALUE IN HEALTH, 2017, 20 (05) : A125 - A125
  • [32] Patterns and Predictors of Rotavirus Vaccine Use among Commercially-Insured U.S: Infants
    Panozzo, Catherine A.
    Brookhart, M. Alan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 360 - 360
  • [33] INITIATION AND DISCONTINUATION OF INTERFERON-CONTAINING THERAPY AMONG HIV/HCV CO-INFECTED PATIENTS IN A US COMMERCIALLY-INSURED POPULATION
    Kirbach, S.
    Wong, B. J. O.
    Kruse, G. B.
    Gooch, K. L.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S343 - S344
  • [34] Long-Term Reductions in Opioid Medication Use After Spinal Stimulation: A Claims Analysis Among Commercially-Insured Population
    Yong, Robert Jason
    Tran, Oth, V
    McGovern, Alysha M.
    Patil, Parag G.
    Gilligan, Christopher J.
    JOURNAL OF PAIN RESEARCH, 2024, 17 : 1773 - 1784
  • [35] Patterns of initiation and discontinuation of medications for opioid use disorder in commercially insured individuals in the US
    Seamans, Marissa J.
    Raman, Sudha R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 400 - 400
  • [36] THE IMPACT OF GENOMIC TESTING ON CHEMOTHERAPY USE AND MEDICAL SPENDING IN A COMMERCIALLY-INSURED POPULATION OF BREAST CANCER PATIENTS
    Epstein, A. J.
    Wong, Y.
    Mitra, N.
    Vachani, A.
    Hin, S.
    Yang, L.
    Smith-McLallen, A.
    Armstrong, K.
    Groeneveld, P. W.
    VALUE IN HEALTH, 2015, 18 (03) : A217 - A218
  • [37] Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
    Funch, Donnie
    Mortimer, Kathleen
    Ziyadeh, Najat J.
    Seeger, John D.
    Li, Ling
    Norman, Heather
    Major-Pedersen, Atheline
    Bosch-Traberg, Heidrun
    Gydesen, Helge
    Dore, David D.
    DIABETES OBESITY & METABOLISM, 2019, 21 (08): : 1837 - 1848
  • [38] Disenrollment Among Commercially-Insured Individuals in the United States with Opioid Use Disorder, 2010-2019
    Rizk, John G.
    Pathan, Uzma
    Saini, Jannat
    DiPaula, Bethany
    Ehret, Megan
    Johnson, Abree
    Qato, Danya M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 632 - 632
  • [39] PREDICTING HIGH-COST DIABETES PATIENTS: AN ANALYSIS OF COMMERCIALLY-INSURED POPULATION
    Zhong, L.
    Huyan, Y.
    Andreyeva, E.
    Smith, M.
    Han, G.
    Carpenter, K.
    Towne, S.
    Jani, S.
    Preston, V
    Ory, M.
    VALUE IN HEALTH, 2023, 26 (06) : S80 - S81
  • [40] Management patterns and costs of atrial fibrillation in a large commercially insured US population
    Fidan, D
    Ollendorf, D
    Leguet, P
    Gabriel, S
    Boccuzzi, S
    VALUE IN HEALTH, 2005, 8 (06) : A92 - A92